GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Current Ratio

Cell MedX (Cell MedX) Current Ratio : 0.10 (As of Feb. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Cell MedX's current ratio for the quarter that ended in Feb. 2024 was 0.10.

Cell MedX has a current ratio of 0.10. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Cell MedX has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Cell MedX's Current Ratio or its related term are showing as below:

CMXC' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.05   Max: 0.28
Current: 0.1

During the past 12 years, Cell MedX's highest Current Ratio was 0.28. The lowest was 0.01. And the median was 0.05.

CMXC's Current Ratio is ranked worse than
98.27% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: 2.74 vs CMXC: 0.10

Cell MedX Current Ratio Historical Data

The historical data trend for Cell MedX's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Current Ratio Chart

Cell MedX Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.09 0.03 0.02 0.04

Cell MedX Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.04 0.02 0.01 0.10

Competitive Comparison of Cell MedX's Current Ratio

For the Medical Devices subindustry, Cell MedX's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell MedX's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's Current Ratio distribution charts can be found below:

* The bar in red indicates where Cell MedX's Current Ratio falls into.



Cell MedX Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Cell MedX's Current Ratio for the fiscal year that ended in May. 2023 is calculated as

Current Ratio (A: May. 2023 )=Total Current Assets (A: May. 2023 )/Total Current Liabilities (A: May. 2023 )
=0.103/2.489
=0.04

Cell MedX's Current Ratio for the quarter that ended in Feb. 2024 is calculated as

Current Ratio (Q: Feb. 2024 )=Total Current Assets (Q: Feb. 2024 )/Total Current Liabilities (Q: Feb. 2024 )
=0.082/0.792
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cell MedX  (OTCPK:CMXC) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Cell MedX Current Ratio Related Terms

Thank you for viewing the detailed overview of Cell MedX's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell MedX (Cell MedX) Business Description

Traded in Other Exchanges
N/A
Address
123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706
Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson 11-11-2016